Trial Profile
A Phase III, Open-label, Multi-Center Study to Evaluate the long term Safety of nemolizumab in Japanese Atopic Dermatitis Patients with moderate to severe pruritus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Adverse reactions; Registrational
- Acronyms Study-JP02
- Sponsors Maruho
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 28 Mar 2022 According to a Maruho media release, the company has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for "Mitchga Subcutaneous Injection 60mg Syringes" for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective) in Japan.
- 02 Nov 2021 Results published in the British Journal of Dermatology